Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE

被引：4

作者：

O'Hara, D. V. ^{[1
,2
]}

Neuen, B. L. ^{[1
,2
]}

Jardine, M. J. ^{[1
,3
]}

机构：

[1] UNSW, George Inst Global Hlth, Sydney, NSW, Australia

[2] Royal North Shore Hosp, Sydney, NSW, Australia

[3] Concord Repatriat Gen Hosp, Sydney, NSW, Australia

来源：

JOURNAL OF NEPHROLOGY | 2020年 / 33卷 / 05期

关键词：

SGLT2; inhibitors; Type; 2; diabetes; Chronic kidney disease; Clinical outcomes; GLOMERULAR-FILTRATION-RATE; DIABETES-MELLITUS; DOUBLE-BLIND; DISEASE; EMPAGLIFLOZIN; CANAGLIFLOZIN; ALBUMINURIA; NEPHROPATHY; MECHANISMS; MORTALITY;

D O I：

10.1007/s40620-020-00809-x

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The burden of diabetic kidney disease is rising rapidly worldwide, and new therapies are of vital importance to reduce the risk of kidney failure and major cardiovascular events. Of the newer glucose-lowering agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown exciting potential in preventing these adverse events. The results of several large cardiovascular outcome trials, a single dedicated kidney outcome trial and a dedicated heart failure trial, demonstrate substantial clinical benefits for several different SGLT2 inhibitors. Emerging evidence raises the possibility that these benefits may extend to those with non-diabetic chronic kidney disease. This review summarises the current evidence for SGLT2 inhibitor benefits and harms, and examines which patients are most likely to gain from these therapies.

引用

页码：977 / 983

页数：7

共 35 条

[1] Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis [J].

Arnott, Clare ;

Li, Qiang ;

Kang, Amy ;

Neuen, Brendon L. ;

Bompoint, Severine ;

Lam, Carolyn S. P. ;

Rodgers, Anthony ;

Mahaffey, Kenneth W. ;

Cannon, Christopher P. ;

Perkovic, Vlado ;

Jardine, Meg J. ;

Neal, Bruce .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (03)

[2] Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts [J].

Astor, Brad C. ;

Matsushita, Kunihiro ;

Gansevoort, Ron T. ;

van der Velde, Marije ;

Woodward, Mark ;

Levey, Andrew S. ;

de Jong, Paul E. ;

Coresh, Josef .

KIDNEY INTERNATIONAL, 2011, 79 (12) :1331-1340

[3] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial [J].

Bailey, Clifford J. ;

Gross, Jorge L. ;

Pieters, Anne ;

Bastien, Arnaud ;

List, James F. .

LANCET, 2010, 375 (9733) :2223-2233

[4] Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial [J].

Barnett, Anthony H. ;

Mithal, Ambrish ;

Manassie, Jenny ;

Jones, Russell ;

Rattunde, Henning ;

Woerle, Hans J. ;

Broedl, Uli C. .

LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (05) :369-384

[5] Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017 [J].

Bikbov, Boris ;

Purcell, Carrie ;

Levey, Andrew S. ;

Smith, Mari ;

Abdoli, Amir ;

Abebe, Molla ;

Adebayo, Oladimeji M. ;

Afarideh, Mohsen ;

Agarwal, Sanjay Kumar ;

Agudelo-Botero, Marcela ;

Ahmadian, Elham ;

Al-Aly, Ziyad ;

Alipour, Vahid ;

Almasi-Hashiani, Amir ;

Al-Raddadi, Rajaa M. ;

Alvis-Guzman, Nelson ;

Amini, Saeed ;

Andrei, Tudorel ;

Andrei, Catalina Liliana ;

Andualem, Zewudu ;

Anjomshoa, Mina ;

Arabloo, Jalal ;

Ashagre, Alebachew Fasil ;

Asmelash, Daniel ;

Ataro, Zerihun ;

Atout, Maha Moh'd Wahbi ;

Ayanore, Martin Amogre ;

Badawi, Alaa ;

Bakhtiari, Ahad ;

Ballew, Shoshana H. ;

Balouchi, Abbas ;

Banach, Maciej ;

Barquera, Simon ;

Basu, Sanjay ;

Bayih, Mulat Tirfie ;

Bedi, Neeraj ;

Bello, Aminu K. ;

Bensenor, Isabela M. ;

Bijani, Ali ;

Boloor, Archith ;

Borzi, Antonio M. ;

Camera, Luis Alberto ;

Carrero, Juan J. ;

Carvalho, Felix ;

Castro, Franz ;

Catala-Lopez, Ferran ;

Chang, Alex R. ;

Chin, Ken Lee ;

Chung, Sheng-Chia ;

Cirillo, Massimo .

LANCET, 2020, 395 (10225) :709-733

[6] The global economic burden of diabetes in adults aged 20-79 years: a cost-of-illness study [J].

Bommer, Christian ;

Heesemann, Esther ;

Sagalova, Vera ;

Manne-Goehler, Jennifer ;

Atun, Rifat ;

Barnighausen, Till ;

Vollmer, Sebastian .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (06) :423-430

[7] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[8] Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial [J].

Cherney, David Z. I. ;

Zinman, Bernard ;

Inzucchi, Silvio E. ;

Koitka-Weber, Audrey ;

Mattheus, Michaela ;

von Eynatten, Maximilian ;

Wanner, Christoph .

LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (08) :610-621

[9] Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention [J].

Gansevoort, Ron T. ;

Correa-Rotter, Ricardo ;

Hemmelgarn, Brenda R. ;

Jafar, Tazeen H. ;

Heerspink, Hiddo J. Lambers ;

Mann, Johannes F. ;

Matsushita, Kunihiro ;

Wen, Chi Pang .

LANCET, 2013, 382 (9889) :339-352

[10] Renoprotective effects of sodium-glucose cotransporter-2 inhibitors [J].

Heerspink, Hiddo J. L. ;

Kosiborod, Mikhail ;

Inzucchi, Silvio E. ;

Cherney, David Z. I. .

KIDNEY INTERNATIONAL, 2018, 94 (01) :26-39

← 1 2 3 4 →